Trial Profile
A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND 70,058
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Fenretinide (Primary) ; Cytarabine; Hydrocortisone; Methotrexate
- Indications Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 17 Mar 2022 Status changed from completed to discontinued.
- 17 Sep 2019 Status changed from active, no longer recruiting to completed.
- 22 May 2017 Status changed from recruiting to active, no longer recruiting.